mobilizing

Dr. Poropatich is an experienced Pulmonary/Critical Care Medicine physician-scientist who serves as the Director of the Center for Military Medicine Research (CMMR), Health Sciences and Professor of Medicine in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh. The Pitt CMMR has been instrumental in building collaborative multi-disciplinary and multi-organizational research teams to improve the health and well-being of service members, veterans and their families that has led to significant DoD medical research collaboration with Pitt. Dr. Poropatich has also been on the faculty at the Uniformed Services University of the Health Science (USUHS) since 1985 and currently serves as an Adjunct Professor of Medicine. Dr. Poropatich served 30 years on active duty in the U.S. Army retiring in 2012 at the rank of Colonel with extended assignments at the Walter Reed National Military Medical Center (1985 to 2012) and the US Army Medical Research and Development Command (2006-2012).

back

next

Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. He is Founder and CEO of Redux Therapeutics, LLC, a clinical-stage small molecule drug development company; Co- Founder and Head of Strategy at C₂Sense, an MIT-based medical diagnostic company; Executive Vice President of SGH2 Energy Global, a developer and operator of waste to green hydrogen projects; and Strategic Advisor and Chief Business Officer of SipNose, Ltd., a pioneering Israeli company delivering drugs direct nose-to-brain to treat a variety of CNS and other brain-related disorders.

back

next

Houman Hemmati is a board-certified ophthalmologist and leader in translational and late-stage drug development. He is presently Chief Medical Officer of Vyluma, Inc., which is developing a pharmacologic treatment for nearsightedness (myopia). He is also Co-Founder and Chief Scientific Officer of aesthetic medicine company Levation Pharma and retina therapeutics company Optigo Biotherapeutics, which is developing long-acting intravitreal drugs for wet macular degeneration and diabetic eye disease. Additionally, he is on the Board of Directors of Trailhead Biosystems (stem cells) and MediPrint Ophthalmics (contact lens drug delivery) and advises a handful of companies in ophthalmology drug development.  He previously served as Director, Clinical Development at Allergan, as Clinical Scientist in the Ophthalmology Therapeutic Area on several Phase 1, 2, and 3 studies, including the Phase 2 study for the program that led to the approval of Vuity to treat presbyopia.

back

next

Mr. Kaufman is the Chief Executive Officer of MAK Capital, an investment advisory firm based in New York, New York, which he founded in 2002. He is director and Chairman of the Board of Agilysys, Inc., and serves as a director for Yatra Online, Inc., Trailhead Biosystems and Metal Recovery Holdings, LLC, (formerly AZP, LLC and American Zinc Recycling). Mr. Kaufman holds a B.A. degree in Economics from the University of Chicago, where he also received his M.B.A. degree. He also earned a law degree from Yale University.

back

next

Mr. Nemiroff has been an analyst at MAK Capital, the New York-based investment advisory firm, since 2016.  He has been in the investments business since 2008.  Previously, Mr. Nemiroff was a Director of Business Development at student lender MRU Holdings and a Manager of Corporate Development at Capital One Financial. Mr. Nemiroff was a strategy consultant at the Boston Consulting Group and practiced corporate law at the firm of Davis Polk & Wardwell in New York. Mr. Nemiroff graduated from Yale Law School and from Princeton University with a degree in economics.

back

next

Dr. Langer has been a member of Noveome’s Board of Directors for over 10 years. He is one of only 12 Institute Professors (MIT’s highest honor). He has written 1,500 articles and has approximately 1350 issued and pending patents. His patents have been licensed or sublicensed to over 400 companies. Dr. Langer has received over 220 major awards including the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 4 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering and Priestley Medal (highest award of the American Chemical Society.) He holds 34 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.

back

next

Mr. Welch formed WeGo Consulting, LLC in Loudon, TN in 2014 after almost 27 years with Allergan, Inc. At Allergan, he was Vice President Sales and Marketing for the U.S. Retina Business Unit, and Vice President, Sales and Marketing for Allergan Medical Dermatology while continuing in his role with U.S. Retina. Outside the U.S., he was Vice President/Managing Director of Allergan Asia Pacific Region for Medical Aesthetics and Neuroscience, as well as President & Managing Director of Allergan Korea. Mr. Welch was also U.S. Director of Marketing, Glaucoma, directing the entire Glaucoma portfolio, and managed the pre-approval planning of RESTASIS^® and LUMIGAN^®. Mr. Welch was also Vice President of the U.S. Managed Healthcare Reimbursement Division and created the initial Government Affairs Operation for Allergan.

back

next